Galena Biopharma (GALE +7.7%) jumps this morning after Aegis Capital initiated the shares with a...
Wednesday, November 28, 2012, 10:37 AM ETGalena Biopharma (GALE +7.7%) jumps this morning after Aegis Capital initiated the shares with a Buy and a $6.00 price target. Aegis says that GALE has developed a novel approach to combating the recurrence of breast cancer in patients with minimal residual disease. The firm's lead candidate, NeuVax, is a peptide vaccine derived from a protein that is the target of several widely used breast cancer treatments. It's currently conducting Phase III trials and is slated to report interim data in late 2013.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles